The incidence rate of thrombosis in intermediate risk revised IPSET-thrombosis (aged >60 years, <i>JAK2</i>-negative, and no history of thrombosis) was very low regardless of the treatment administered (0.9% and 0% per year with and without cytoreduction, respectively). The gene discussed is JAK2; the disease is deep vein thrombosis.